CSIMarket
 
Spero Therapeutics Inc   (SPRO)
Other Ticker:  
 
 
Price: $1.7900 $0.05 2.874%
Day's High: $1.84 Week Perf: 2.87 %
Day's Low: $ 1.68 30 Day Perf: 21.36 %
Volume (M): 1,084 52 Wk High: $ 2.00
Volume (M$): $ 1,941 52 Wk Avg: $1.45
Open: $1.71 52 Wk Low: $0.99



 Market Capitalization (Millions $) 94
 Shares Outstanding (Millions) 53
 Employees -
 Revenues (TTM) (Millions $) 78
 Net Income (TTM) (Millions $) -2
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 0

Spero Therapeutics Inc
Spero Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies to treat multi-drug resistant bacterial infections. The company utilizes its expertise in antimicrobial resistance and drug discovery to develop innovative antibiotics and combination therapies. Spero Therapeutics aims to address the urgent need for new treatments against drug-resistant bacteria, which pose a significant threat to global health. They are committed to developing safe and effective drugs that can combat these infectious diseases and improve patient outcomes.


   Company Address: 675 Massachusetts Avenue, Cambridge 2139 MA
   Company Phone Number: 242-1600   Stock Exchange / Ticker: NASDAQ SPRO
   SPRO is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Clearing a Path for Hope: Spero Therapeutics Advances Novel Polymyxin Antibiotic to Combat Multi-Drug Resistant Gram-Negative Bacterial Infections

Published Wed, Feb 28 2024 1:05 PM UTC

In a significant development, Spero Therapeutics, a renowned clinical-stage biopharmaceutical company, has announced that its investigational new drug (IND) application for SPR206 has received clearance from the U.S. Food and Drug Administration (FDA). This achievement has opened the doors for a Phase 2 clinical study to evaluate the efficacy of SPR206, a next-generation pol...

Clinical Study

Reimagining Antibiotics: Tebipenem HBr Offers Hope for Resistant Urinary Tract Infections

Published Tue, Jan 2 2024 1:05 PM UTC

In recent years, the rise of antibiotic-resistant bacteria has posed a significant challenge in the treatment of complicated urinary tract infections (cUTIs). To address this issue, Spero Therapeutics, a leading biopharmaceutical company, has announced the commencement of the Phase 3 PIVOT-PO trial, evaluating the efficacy and safety of Tebipenem HBr in the treatment of cUTI...

Spero Therapeutics Inc

Spero Therapeutics Inc Shatters Expectations with Over 100% Revenue Surge in Exceptional 3Q 2023 Earnings Season

Spero Therapeutics Inc, a multi-asset clinical-stage biopharmaceutical company, has seen a drop in its shares over the past five trading days. The shares have decreased by -4.31%, leading to a year-to-date performance of -36.21%. Despite this decline, the shares still trade 12.1% above their 52-week low.
In terms of the company's financial performance, Spero Therapeutics Inc reported a loss per share of $-0.06 for the financial third quarter of 2023. This is an improvement compared to a loss per share of $-0.33 in the same quarter a year ago. Additionally, earnings per share improved from $-0.23 in the previous quarter. These figures indicate positive progress for the company.

Spero Therapeutics Inc

Spero Therapeutics Inc Showcases Unprecedented Innovation in Execution from April to June 30, 2023



In the face of a challenging environment within the Major Pharmaceutical Preparations sector, Spero Therapeutics Inc has showcased impressive financial results for the April to June 30, 2023 fiscal interval. The company has demonstrated significant improvements in loss per share, earnings per share, and revenue growth. Furthermore, Spero Therapeutics Inc's sustained reduction in net deficit and rising accounts receivable indicate promising future prospects.
Improved Earnings Metrics:
Spero Therapeutics Inc has managed to decrease its loss per share from $-0.87 to $-0.23 when compared to the previous fiscal year. This signifies a positive trend towards profitability and highlights the company's efforts to streamline operations and control costs. Additionally, the earnings per share have shown an uptick, increasing from $-0.25 in the previous quarter to an improved amount.

Spero Therapeutics Inc

Spero Therapeutics Inc Struggles with Lackluster Revenue in the First Quarter of 2023 Earnings Season

Spero Therapeutics Inc, a biopharmaceutical company that focuses on developing treatments for multi-drug resistant bacterial infections, recently released its financial results for the fiscal year that ended on March 31, 2023.
According to the report, Spero Therapeutics Inc suffered a loss of $-0.25 per share, compared to a loss of $-1.01 per share in the previous fiscal year. Although the company faced a loss, it did increase its earnings per share from $0.51 in the previous reporting season to $-0.25 in the recent fiscal year.






 

Spero Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com